Switzerland: Merck expands neurology pipeline with acquisition of Chord Therapeutics

Merck, a Germany-based leading science and technology company, has expanded its neurology pipeline with the acquisition of Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases. The acquisition secures Merck the global rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). The transaction is…

You must be a HMI Subscriber to view this content.

Subscribe Now »